DRG 670 Overview

DRG 670 encompasses transurethral procedures without Complication or Comorbidity or Major Complication or Comorbidity, typically including endoscopic interventions on the bladder, prostate, or urethra performed via the transurethral route. This Diagnosis-Related Group captures cases with comparatively lower resource use and shorter hospital stays than cases with complications. It matters for Medicare payment because it defines the inpatient payment bundle and relative weight used by the Centers for Medicare & Medicaid Services to reimburse hospitals for these straightforward endoscopic urologic procedures. Accurate assignment affects hospital revenue and case-mix reporting.

• Acute procedural optimization studies: Trials comparing different transurethral surgical techniques or procedural adjuncts (for example, energy sources, resection vs. enucleation approaches, or use of intraoperative imaging/visualization tools) in patients undergoing transurethral procedures for obstructive lower urinary tract pathology. These studies enroll predominantly older adults with benign prostatic hyperplasia, bladder outlet obstruction, or non–muscle invasive bladder lesions who require an inpatient or same-day surgical procedure; the objective is to measure perioperative metrics such as operative time, blood loss, complication rates, and length of stay. Results are directly relevant to providers and payers because improved procedural efficiency and lower complication rates can reduce inpatient resource use and readmissions associated with this DRG.
• Comparative effectiveness and risk-stratification studies: Prospective cohort or randomized studies that compare less-invasive transurethral approaches to alternative management strategies (for example, endoscopic intervention versus medical management or staged procedures) and evaluate outcomes across risk strata (older patients, anticoagulation use, or significant comorbidities). These trials focus on real-world effectiveness, functional outcomes (urinary flow, symptom scores), and safety in diverse inpatient populations to identify which subgroups benefit most from specific procedural choices. Findings inform clinical decision-making and utilization management for payers by clarifying which patients derive meaningful benefit from inpatient transurethral procedures and which could be managed conservatively or in an outpatient setting.
• Post-discharge outcomes and health services research: Observational studies and registry-based research examining 30- and 90-day outcomes after transurethral procedures, including readmissions, postoperative infections, urinary retention, need for re-intervention, and patient-reported quality-of-life measures. These studies often target transition-of-care issues in older adults and those with multimorbidity to identify predictors of adverse post-discharge events and opportunities for care coordination or rehabilitation services. For providers and payers, this evidence highlights drivers of downstream utilization and costs tied to this DRG and supports development of targeted pathways to reduce readmissions and optimize post-discharge resource allocation.